Skip to main content
Premium Trial:

Request an Annual Quote

Nuvectis Pharma Grows Precision Oncology Pipeline With University of Edinburgh's SRC/YES1 Inhibitor

NEW YORK – Nuvectis Pharma on Tuesday said it has licensed exclusive worldwide rights to develop and commercialize an SRC/YES1 inhibitor discovered by the University of Edinburgh in Scotland.

The Fort Lee, New Jersey-based company will begin studies of the drug, called NXP900, in Q4 2021 that will support the submission of an investigational new drug application to the US Food and Drug Administration.

Previous research has found that SRC signaling occurs in several solid tumor types, including breast, colon, prostate, pancreatic and ovarian cancer, while YES1 amplification has been identified in lung, head and neck, esophageal, and sarcoma tumors. Researchers have found, for example, that EGFR-mutated lung cancer patients can become resistant to EGFR inhibitors through acquired YES1 amplifications in their tumors.

In preclinical studies, NXP900 inhibited the activity of SRC and YES1 kinases at sub-nanomolar concentrations. In in vivo studies of breast cancer xenograft models, NXP900 also inhibited primary and metastatic tumor growth. 

This is the second drug Nuvectis has licensed this year. Last month, Nuvectis licensed an HSF1 pathway inhibitor from the UK's CRT Pioneer Fund and raised $15 million in a Series A preferred stock financing round. "We believe that with our two pipeline products, we are now one step closer to creating a diversified precision medicine oncology-focused company with the goal of helping more people in their fight against hard-to-treat cancers," Nuvectis CEO Ron Bentsur said in a statement.